Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | unknown | PO / MO |
The patient accidentally took the third capsule of Vivotif the day after the second capsule; Case reference number US-BN-2025-001609 is a spontaneous case initially received from a consumer via Communications (reference number: USBAV25-2407) on 26-Sep-2025 and concerns a 66-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 22-Sep-2025, the patient took the first dose of Vivotif (batch number: unknown), orally, at an unknown dose, for the indication of vaccination. On 24-Sep-2025, two days after the first dose, the patient took the second dose of Vivotif (batch number: unknown) orally, at an unknown dose. On 25-Sep-2025, three days after the first dose, the patient took the third dose of Vivotif (batch number: unknown) orally, at an unknown dose (explicitly coded as 'inappropriate schedule of vaccine administered') At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: This case concerns a 66-year-old male patient, as reported, received the third dose of Vivotif, one day after the second dose for the indication of vaccination, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 66-year-old male patient, as reported, received the third dose of Vivotif, one day after the second dose for the indication of vaccination, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.